Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
Abstract Discontinuing long‐term pharmacotherapy for insomnia can result in rebound insomnia or withdrawal symptoms and suboptimal treatment. Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a phase III, 12‐month, global, multicenter, randomized,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13470 |
| _version_ | 1797849006429175808 |
|---|---|
| author | Yoshikazu Takaesu Masahiro Suzuki Margaret Moline Kate Pinner Kanako Inabe Yurie Nishi Kenichi Kuriyama |
| author_facet | Yoshikazu Takaesu Masahiro Suzuki Margaret Moline Kate Pinner Kanako Inabe Yurie Nishi Kenichi Kuriyama |
| author_sort | Yoshikazu Takaesu |
| collection | DOAJ |
| description | Abstract Discontinuing long‐term pharmacotherapy for insomnia can result in rebound insomnia or withdrawal symptoms and suboptimal treatment. Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a phase III, 12‐month, global, multicenter, randomized, double‐blind, parallel‐group study who completed 12 or 6 months of active treatment and follow‐up period. Study E2006‐G000‐303 (Study 303) included adults (N = 655) with subjective sleep‐onset latency ≥30 min and/or subjective wake‐after‐sleep onset ≥60 min at least three times weekly during the 4 weeks before enrollment. Subjects were randomized 1:1:1 to lemborexant 5 mg (LEM5) or 10 mg (LEM10) or placebo for 6 months. Thereafter, for an additional 6 months, LEM5‐ and LEM10‐treated subjects continued lemborexant and the placebo group was rerandomized 1:1 to LEM5 or LEM10. Month 12 was followed by abrupt discontinuation and a 2‐week end‐of‐study follow‐up. Using daily electronic sleep diaries, patients reported (subjective) sleep end points (sleep‐onset latency, wake‐after‐sleep onset, sleep efficiency, and total sleep time). Withdrawal symptoms were assessed using the Tyrer Benzodiazepine Withdrawal Symptoms Questionnaire (T‐BWSQ). Sleep outcome improvements with lemborexant at month 12 were generally maintained throughout the 2‐week off‐treatment period wherein <20% of subjects experienced significant worsening of insomnia symptoms versus screening. There was no evidence of withdrawal symptoms by T‐BWSQ following lemborexant discontinuation. This analysis demonstrates rebound insomnia is unlikely to occur with lemborexant, and its effectiveness is maintained after abrupt discontinuation without placebo replacement following 6–12 months of treatment. |
| first_indexed | 2024-04-09T18:36:51Z |
| format | Article |
| id | doaj.art-e3daed50698f49e49e0ccb649ef883aa |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-04-09T18:36:51Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-e3daed50698f49e49e0ccb649ef883aa2023-04-11T09:22:04ZengWileyClinical and Translational Science1752-80541752-80622023-04-0116458159210.1111/cts.13470Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trialYoshikazu Takaesu0Masahiro Suzuki1Margaret Moline2Kate Pinner3Kanako Inabe4Yurie Nishi5Kenichi Kuriyama6Department of Neuropsychiatry, Graduate School of Medicine University of the Ryukyus Okinawa JapanDepartment of Psychiatry Nihon University School of Medicine Tokyo JapanEisai Inc. Nutley New Jersey USAEisai Ltd. Hatfield UKEisai Co., Ltd. Tokyo JapanEisai Co., Ltd. Tokyo JapanDepartment of Sleep‐Wake Disorders, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo JapanAbstract Discontinuing long‐term pharmacotherapy for insomnia can result in rebound insomnia or withdrawal symptoms and suboptimal treatment. Post hoc analyses evaluated rebound insomnia and withdrawal symptoms among the subset of subjects from a phase III, 12‐month, global, multicenter, randomized, double‐blind, parallel‐group study who completed 12 or 6 months of active treatment and follow‐up period. Study E2006‐G000‐303 (Study 303) included adults (N = 655) with subjective sleep‐onset latency ≥30 min and/or subjective wake‐after‐sleep onset ≥60 min at least three times weekly during the 4 weeks before enrollment. Subjects were randomized 1:1:1 to lemborexant 5 mg (LEM5) or 10 mg (LEM10) or placebo for 6 months. Thereafter, for an additional 6 months, LEM5‐ and LEM10‐treated subjects continued lemborexant and the placebo group was rerandomized 1:1 to LEM5 or LEM10. Month 12 was followed by abrupt discontinuation and a 2‐week end‐of‐study follow‐up. Using daily electronic sleep diaries, patients reported (subjective) sleep end points (sleep‐onset latency, wake‐after‐sleep onset, sleep efficiency, and total sleep time). Withdrawal symptoms were assessed using the Tyrer Benzodiazepine Withdrawal Symptoms Questionnaire (T‐BWSQ). Sleep outcome improvements with lemborexant at month 12 were generally maintained throughout the 2‐week off‐treatment period wherein <20% of subjects experienced significant worsening of insomnia symptoms versus screening. There was no evidence of withdrawal symptoms by T‐BWSQ following lemborexant discontinuation. This analysis demonstrates rebound insomnia is unlikely to occur with lemborexant, and its effectiveness is maintained after abrupt discontinuation without placebo replacement following 6–12 months of treatment.https://doi.org/10.1111/cts.13470 |
| spellingShingle | Yoshikazu Takaesu Masahiro Suzuki Margaret Moline Kate Pinner Kanako Inabe Yurie Nishi Kenichi Kuriyama Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial Clinical and Translational Science |
| title | Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial |
| title_full | Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial |
| title_fullStr | Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial |
| title_full_unstemmed | Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial |
| title_short | Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial |
| title_sort | effect of discontinuation of lemborexant following long term treatment of insomnia disorder secondary analysis of a randomized clinical trial |
| url | https://doi.org/10.1111/cts.13470 |
| work_keys_str_mv | AT yoshikazutakaesu effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT masahirosuzuki effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT margaretmoline effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT katepinner effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT kanakoinabe effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT yurienishi effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial AT kenichikuriyama effectofdiscontinuationoflemborexantfollowinglongtermtreatmentofinsomniadisordersecondaryanalysisofarandomizedclinicaltrial |